PDF herunterladen
Adipositas - Ursachen, Folgeerkrankungen, Therapie 2009; 03(03): 158-163
DOI: 10.1055/s-0037-1618681
Hypertonie Hypertonie
Schattauer GmbH

Angriffspunkt für eine antihypertensive Therapie?

Das Renin-Angiotensin-Aldosteron-System bei Adipositas
Stefan Engeli Dr. med.
1   Institut für Klinische Pharmakologie, Medizinische Hochschule Hannover
,
Jens Jordan Prof. Dr. med.
1   Institut für Klinische Pharmakologie, Medizinische Hochschule Hannover
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
22. Dezember 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

In Lehrbüchern der Inneren Medizin wird vermittelt, dass bei der Mehrzahl der Patienten mit arterieller Hypertonie keine Ursache für den Blutdruckanstieg nachgewiesen werden kann. Diese Patienten werden in die Rubrik „essenzielle” Hypertonie eingeteilt. Sekundäre Hypertonieformen sind demnach sehr selten. Da die arterielle Hypertonie aber durch Adipositas hervorgerufen oder verstärkt wird, ist diese Sichtweise insbesondere vor dem Hintergrund der massiven Zunahme der Adipositas-Prävalenz in den letzten Jahren kritisch zu hinterfragen.

 

  • Literatur

  • 1 Barnett AH, Bain SC, Bouter P. et al. Angiotensinreceptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-1961.
    CrossrefPubMedGoogle Scholar
  • 2 Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96: 939-949.
    CrossrefPubMedGoogle Scholar
  • 3 Bosch J, Yusuf S, Gerstein HC. et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551-1562.
    CrossrefPubMedGoogle Scholar
  • 4 Bramlage P, Pittrow D, Wittchen HU. et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004; 17: 904-910.
    CrossrefPubMedGoogle Scholar
  • 5 Brown CD, Higgins M, Donato KA. et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 2000; 08: 605-619.
    CrossrefPubMedGoogle Scholar
  • 6 Dahlof B, Devereux RB, Kjeldsen SE. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
    CrossrefPubMedGoogle Scholar
  • 7 De Paula RB, Da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004; 43: 41-47.
    CrossrefPubMedGoogle Scholar
  • 8 Despres JP. Is visceral obesity the cause of the metabolic syndrome?. Ann Med 2006; 38: 52-63.
    CrossrefPubMedGoogle Scholar
  • 9 Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A. et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 2003; 100: 14211-14216.
    CrossrefPubMedGoogle Scholar
  • 10 Eikelis N, Schlaich M, Aggarwal A. et al. Interactions between leptin and the human sympathetic nervous system. Hypertension 2003; 41: 1072-1079.
    CrossrefPubMedGoogle Scholar
  • 11 Engeli S, Bohnke J, Gorzelniak K. et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45: 356-362.
    CrossrefPubMedGoogle Scholar
  • 12 Engeli S, Schling P, Gorzelniak K. et al. The adiposetissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?. Int J Biochem Cell Biol 2003; 35: 807-825.
    CrossrefPubMedGoogle Scholar
  • 13 Engeli S, Sharma AM. The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J Mol Med 2001; 79: 21-29.
    CrossrefPubMedGoogle Scholar
  • 14 Esler M, Straznicky N, Eikelis N. et al. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 2006; 48: 787-796.
    CrossrefPubMedGoogle Scholar
  • 15 Gorzelniak K, Engeli S, Janke J. et al. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens 2002; 20: 965-973.
    CrossrefPubMedGoogle Scholar
  • 16 Grassi G, Seravalle G, Dell’Oro R. et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21: 1761-1769.
    CrossrefPubMedGoogle Scholar
  • 17 Jordan J, Engeli S, Boschmann M. et al. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients. J Hypertens 2005; 23: 2313-2318.
    CrossrefPubMedGoogle Scholar
  • 18 Jordan J, Engeli S, Boye SW. et al. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007; 49: 1047-1055.
    CrossrefPubMedGoogle Scholar
  • 19 Julius S, Kjeldsen SE, Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.
    CrossrefPubMedGoogle Scholar
  • 20 Lindholm LH, Ibsen H, Borch-Johnsen K. et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879-1886.
    CrossrefPubMedGoogle Scholar
  • 21 Mann JF, Schmieder RE, McQueen M. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553.
    CrossrefPubMedGoogle Scholar
  • 22 Massiera F, Bloch-Faure M, Ceiler D. et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001; 15: 2727-2729.
    CrossrefPubMedGoogle Scholar
  • 23 Mikhail N, Golub MS, Tuck ML. Obesity and hypertension. Prog Cardiovasc Dis 1999; 42: 39-58.
    CrossrefPubMedGoogle Scholar
  • 24 Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925-930.
    CrossrefPubMedGoogle Scholar
  • 25 Parving HH, Lehnert H, Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
    CrossrefPubMedGoogle Scholar
  • 26 Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005; 45: 9-14.
    CrossrefPubMedGoogle Scholar
  • 27 Reisin E, Weir MR, Falkner B. et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension 1997; 30: 140-145.
    CrossrefPubMedGoogle Scholar
  • 28 Rossing K, Schjoedt KJ, Jensen BR. et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005; 68: 1190-1198.
    CrossrefPubMedGoogle Scholar
  • 29 Ruano M, Silvestre V, Castro R. et al. Morbid obesity, hypertensive disease and the renin-angiotensinaldosterone axis. Obes Surg 2005; 15: 670-676.
    CrossrefPubMedGoogle Scholar
  • 30 Ruggenenti P, Fassi A, Ilieva AP. et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951.
    CrossrefPubMedGoogle Scholar
  • 31 Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A metaanalysis of randomised clinical trials. Diabetes Metab 2004; 30: 487-496.
    CrossrefPubMedGoogle Scholar
  • 32 Scholze J, Grimm E, Herrmann D. et al. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. Circulation 2007; 115: 1991-1998.
    CrossrefPubMedGoogle Scholar
  • 33 Schorr U, Blaschke K, Turan S. et al. Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. J Hypertens 1998; 16: 1475-1480.
    CrossrefPubMedGoogle Scholar
  • 34 Sjostrom L, Lindroos AK, Peltonen M. et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-2693.
    CrossrefPubMedGoogle Scholar
  • 35 The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
    CrossrefPubMed
  • 36 The Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000; 355: 253-259.
    PubMedGoogle Scholar
  • 37 Tuck ML, Sowers J, Dornfeld L. et al. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981; 304: 930-933.
    CrossrefPubMedGoogle Scholar
  • 38 Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678.
    CrossrefPubMedGoogle Scholar
  • 39 Yusuf S, Sleight P, Pogue J. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
    CrossrefPubMedGoogle Scholar